A citation-based method for searching scientific literature

Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, Lisa M Crocker, Kathryn L Parsons, Elaine Mai, Walter A Blättler, John M Lambert, Ravi V J Chari, Robert J Lutz, Wai Lee T Wong, Frederic S Jacobson, Hartmut Koeppen, Ralph H Schwall, Sara R Kenkare-Mitra, Susan D Spencer, Mark X Sliwkowski. Cancer Res 2008
Times Cited: 1019







List of co-cited articles
1016 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
38

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa,[...]. Clin Cancer Res 2016
278
30

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani,[...]. N Engl J Med 2020
491
26

Strategies and challenges for the next generation of antibody-drug conjugates.
Alain Beck, Liliane Goetsch, Charles Dumontet, Nathalie Corvaïa. Nat Rev Drug Discov 2017
939
21

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
784
20

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
19

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
18

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Véronique Diéras, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E Krop, Kim Blackwell, Silke Hoersch, Jin Xu,[...]. Lancet Oncol 2017
257
18

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio Gonzalez Martin, Patricia M LoRusso, Jean-Marc Ferrero, Tanja Badovinac-Crnjevic, Silke Hoersch, Melanie Smitt, Hans Wildiers. Lancet Oncol 2017
227
16

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Teemu T Junttila, Guangmin Li, Kathryn Parsons, Gail Lewis Phillips, Mark X Sliwkowski. Breast Cancer Res Treat 2011
306
14

Trastuzumab emtansine: mechanisms of action and drug resistance.
Mark Barok, Heikki Joensuu, Jorma Isola. Breast Cancer Res 2014
255
14


Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman,[...]. N Engl J Med 2006
13

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara,[...]. Lancet Oncol 2017
171
12

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Michael J Birrer, Kathleen N Moore, Ilaria Betella, Richard C Bates. J Natl Cancer Inst 2019
131
11

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders,[...]. N Engl J Med 2020
379
11

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
11


Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, Edmund A Rossi, Robert M Sharkey. Oncotarget 2015
164
10

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im, Roberto Hegg, Young-Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pienkowski, Adam Knott,[...]. N Engl J Med 2012
10

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, Xinzhong Wang, Leslie K Wetzel, Marlon C Rebelatto, Mary Jane Masson Hinrichs, Binyam Z Bezabeh, Ryan L Fleming, Nazzareno Dimasi,[...]. Cancer Cell 2016
169
10

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Philip R Hamann, Lois M Hinman, Irwin Hollander, Carl F Beyer, Delores Lindh, Ryan Holcomb, William Hallett, Hwei-Ru Tsou, Janis Upeslacis, Dan Shochat,[...]. Bioconjug Chem 2002
372
10


Cleavable linkers in antibody-drug conjugates.
Jonathan D Bargh, Albert Isidro-Llobet, Jeremy S Parker, David R Spring. Chem Soc Rev 2019
132
10

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Ian E Krop, Muralidhar Beeram, Shanu Modi, Suzanne F Jones, Scott N Holden, Wei Yu, Sandhya Girish, Jay Tibbitts, Joo-Hee Yi, Mark X Sliwkowski,[...]. J Clin Oncol 2010
383
9

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Hyun-Soo Cho, Karen Mason, Kasra X Ramyar, Ann Marie Stanley, Sandra B Gabelli, Dan W Denney, Daniel J Leahy. Nature 2003
9

Antibody-drug conjugates for cancer.
Cindy H Chau, Patricia S Steeg, William D Figg. Lancet 2019
180
9

Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki,[...]. N Engl J Med 2011
9

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
94
8


Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
207
8


Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio González-Martín, Patricia M LoRusso, Jean-Marc Ferrero, Melanie Smitt, Ron Yu, Abraham C F Leung, Hans Wildiers. Lancet Oncol 2014
399
8

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Edith A Perez, Carlos Barrios, Wolfgang Eiermann, Masakazu Toi, Young-Hyuck Im, Pierfranco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier Pivot, Howard Burris,[...]. J Clin Oncol 2017
203
8

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
227
8

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
285
8

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O'Brien, Kongming Wang, Tao Wang,[...]. N Engl J Med 2016
679
8

Antibody-drug conjugates: an emerging concept in cancer therapy.
Ravi V J Chari, Michael L Miller, Wayne C Widdison. Angew Chem Int Ed Engl 2014
571
8

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Sara A Hurvitz, Miguel Martin, Kyung Hae Jung, Chiun-Sheng Huang, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau,[...]. J Clin Oncol 2019
73
10

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Kevin J Hamblett, Peter D Senter, Dana F Chace, Michael M C Sun, Joel Lenox, Charles G Cerveny, Kim M Kissler, Starr X Bernhardt, Anastasia K Kopcha, Roger F Zabinski,[...]. Clin Cancer Res 2004
724
8

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Jagath R Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D Leipold, Sylvia Weir, Yvonne Chen, Michelle Simpson, Siao Ping Tsai, Mark S Dennis,[...]. Nat Biotechnol 2008
798
8

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Pia M Challita-Eid, Daulet Satpayev, Peng Yang, Zili An, Karen Morrison, Yuriy Shostak, Arthur Raitano, Rossana Nadell, Wendy Liu, Dawn Ratay Lortie,[...]. Cancer Res 2016
174
8


HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
215
8

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil. Int J Mol Sci 2019
77
10

Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Steven Coats, Marna Williams, Benjamin Kebble, Rakesh Dixit, Leo Tseng, Nai-Shun Yao, David A Tice, Jean-Charles Soria. Clin Cancer Res 2019
130
7

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Alexander N Starodub, Allyson J Ocean, Manish A Shah, Michael J Guarino, Vincent J Picozzi, Linda T Vahdat, Sajeve S Thomas, Serengulam V Govindan, Pius P Maliakal, William A Wegener,[...]. Clin Cancer Res 2015
134
7

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Philipp Müller, Matthias Kreuzaler, Tarik Khan, Daniela S Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Nitz, Oleg Gluz,[...]. Sci Transl Med 2015
174
7

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D J Slamon, W Godolphin, L A Jones, J A Holt, S G Wong, D E Keith, W J Levin, S G Stuart, J Udove, A Ullrich. Science 1989
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.